Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.1.99.3 (
PRE
)
1,923
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The nontransformed steroid receptors contain several non-steroid binding proteins, such as hsp90, hsp70, and p59. Recently, we and others have shown that p59 (FKBP59) is an immunophilin which binds two potent immunosuppressants,
FK506
and rapamycin. This raises the possibility that
FK506
or rapamycin may modify the function of steroid receptors. To develop this line of inquiry, we chose a yeast model system in which the human progesterone receptor form B (hPR-B) was cotransformed with a reporter gene. The reporter contains two copies of a progesterone response element/glucocorticoid response element (
PRE
/GRE) upstream of the CYC1 promoter which are linked to the lacZ gene of Escherichia coli. We found that
FK506
potentiated the ability of progesterone in activating transcription. To gain insight into the mechanism of
FK506
's regulation of PR action, we questioned whether calcineurin is involved, because it has been shown that
FK506
is a specific inhibitor of calcineurin, a Ca(2+)- and calmodulin-regulated phosphatase, through the formation of an FKBP12-
FK506
-calcineurin-calmodulin complex. We found that 15-O-desmethyl-FK520, an
FK506
analogue which is an excellent ligand of FKBP12, but a poor inhibitor of calcineurin, failed to induce the same effect as
FK506
. We also found that calmidazolium, a calmodulin antagonist, mimicked
FK506
's action. Furthermore, immunoblot analysis showed that both
FK506
and calmidazolium potentiated the effect of progesterone in decreasing the mobility of hPR-B upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This suggests that
FK506
and calmidazolium may cooperate with progesterone in increasing the level of hPR-B phosphorylation.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. 752 Dec 10